How Soon Is Now? The Urgent Need for Randomized, Controlled Trials Evaluating Treatment of Multidrug‐Resistant Bacterial Infection | Zendy

David L. Paterson | Zendy; Benjamin A. Rogers | Zendy

Open Access

How Soon Is Now? The Urgent Need for Randomized, Controlled Trials Evaluating Treatment of Multidrug‐Resistant Bacterial Infection

Author(s) -

David L. Paterson,

Benjamin A. Rogers

Publication year - 2010

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/657243

Subject(s) - acinetobacter baumannii , microbiology and biotechnology , pseudomonas aeruginosa , multilocus sequence typing , multiple drug resistance , medicine , antibiotic resistance , antibiotics , enterobacteriaceae , biology , escherichia coli , virology , bacteria , genetics , gene , genotype

Antibiotic resistance among gram-negative bacilli shows no signs of abatement. Resistance of Pseudomonas aeruginosa, Acinetobacter baumannii, and the Enterobacteriaceae to multiple antibiotic classes is a growing clinical problem worldwide [1]. Two trends are particularly noteworthy. First, there has been increased recognition of successful antibiotic-resistant clones appearing in multiple geographic regions. Multilocus sequence typing analyses of contemporary collections of multidrug-resistant strains have shown that carbapenem-resistant A. baumannii ST92 [2], K. pneumoniae carbapenemase–producing K. pneumoniae ST258 [3], and extended-spectrum b-lactamase–producing Escherichia coli ST131 [4] are global problems. Second, new mechanisms of multidrug resistance are becoming evident. These include aminoglycoside 16S ribosomal RNA methylation [5] and production of the New Delhi metallo-b-lactamase [6].

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research